# bluebird bio, Inc.

bluebird bio, Inc. is a company headquartered in Somerville, MA, United States.

## Company overview

- **Legal name:** bluebird bio, Inc.
- **Former names in filing history:** Genetix Pharmaceuticals Inc (2004-06-14 to 2010-03-19)
- **Classification:** Company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** Somerville, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001293971

## About

bluebird bio, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001293971, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2025-03-27, it reported annual revenue of USD 83,807,000; net income of USD -240,715,000; total assets of USD 460,232,000 for the fiscal period ended 2024-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2024 (period ended 2024-12-31)

- **Revenue:** $83.8M (USD 83,807,000)
- **Net income:** -$240.7M (USD -240,715,000)
- **Total assets:** $460.2M (USD 460,232,000)
- **Cash and equivalents:** $62.3M (USD 62,305,000)
- **Operating cash flow:** -$260.0M (USD -260,020,000)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $29.5M (USD 29,497,000)
- **Net income:** -$211.9M (USD -211,913,000)
- **Total assets:** $619.2M (USD 619,161,000)
- **Cash and equivalents:** $221.8M (USD 221,755,000)
- **Operating cash flow:** -$235.0M (USD -235,046,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $3.6M (USD 3,597,000)
- **Net income:** -$266.6M (USD -266,578,000)
- **Total assets:** $554.9M (USD 554,902,000)
- **Cash and equivalents:** $113.0M (USD 113,006,000)
- **Operating cash flow:** -$353.0M (USD -352,953,000)
- **Later filings:** Revenue, Net income, Total assets, Operating cash flow: shown as originally filed; later filings report different values for the same periods.

### FY2021 (period ended 2021-12-31)

- **Revenue:** $3.7M (USD 3,662,000)
- **Net income:** -$819.4M (USD -819,378,000)
- **Total assets:** $593.8M (USD 593,795,000)
- **Cash and equivalents:** $161.2M (USD 161,160,000)
- **Operating cash flow:** -$635.6M (USD -635,639,000)

## Recent SEC filings

- Form 8-K — filed 2025-06-02 — period 2025-06-02 — 8-K
- Form 10-Q — filed 2025-05-14 — period 2025-03-31 — 10-Q
- Form 8-K — filed 2025-05-14 — period 2025-05-13 — 8-K
- Form 8-K — filed 2025-03-28 — period 2025-03-28 — 8-K
- Form 10-K — filed 2025-03-27 — period 2024-12-31 — 10-K
- Form 8-K — filed 2025-02-21 — period 2025-02-21 — 8-K
- Form 8-K — filed 2025-02-20 — period 2025-02-13 — 8-K
- Form 8-K — filed 2024-12-13 — period 2024-12-12 — 8-K
- Form 8-K — filed 2024-12-04 — period 2024-12-04 — 8-K
- Form 10-Q — filed 2024-11-14 — period 2024-09-30 — 10-Q
- Form 8-K — filed 2024-11-14 — period 2024-11-14 — 8-K
- Form SC 13G — filed 2024-11-08

---

Updated: 2026-10-23T20:08:00Z

Canonical page: https://altss.com/profile/bluebird-bio-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology